Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)

• Status: Terminated
• Trial end date: 2004-11-01
• Target enrollment: 0
• Participant gender: All

Summary

NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed with the 'parkinson plus' syndromes of multiple system atrophy (MSA) and progressive supranuclear plasy (PSP). In addition to showing whether riluzole is helpful in MSA and PSP, NNIPPS will improve criteria for making an accurate and early diagnosis, for assessing the rate of progression, and will advance understanding of the biology of these disabling and progressive neurodegenerative diseases.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King's College London
• Collaborators: Assistance Publique - Hôpitaux de Paris; Aventis Pharmaceuticals; University of Ulm
• Treatments: Riluzole

Criteria

Inclusion Criteria:

• akinetic rigid syndrome plus clinical criteria for MSA or PSP

Exclusion Criteria:

• Idiopathic Parkinson's disease

• Other neurological or serious medical disorders

• Unable to give informed consent

• dementia

• liver damage

• women of child bearing age unable to use effective method of contraception